New Hepatitis B Treatment Silences Virus in Early Trials

More than 250 million people worldwide could soon have a real cure for chronic hepatitis B, thanks to a revolutionary therapy that silences the virus instead of cutting DNA.

Scientists at nChroma Bio in Boston have developed a treatment that places chemical tags on the hepatitis B virus to shut it down completely. Unlike traditional gene editing that makes risky cuts to DNA strands, this epigenetic approach simply turns off the virus like flipping a light switch.

The therapy worked remarkably well in laboratory tests on human liver cells and mice. When researchers tested it in monkeys, the animals experienced only minimal and temporary side effects. A single injection proved "quite impressive" in its ability to silence the virus, according to John Tavis, a molecular virologist at Saint Louis University.

Hepatitis B is notoriously difficult to cure because the virus hides inside liver cells as mini-chromosomes that act like a genomic archive. Current drugs can control the infection, but less than 10% of patients can safely stop their daily medications after 10 years of treatment. When people do stop, the virus often roars back with dangerous rebounds.

The new treatment, called CRMA-1001, uses a modified version of the CRISPR Cas9 enzyme that doesn't cut DNA. Instead, it delivers methyl groups that tag both the hidden viral DNA and pieces that have integrated into human chromosomes. This dual action prevents the virus from replicating and stops it from producing proteins that trick the immune system.

Angelo Lombardo, a molecular biologist who co-founded nChroma Bio, says the preclinical findings supported moving forward with human trials. The first participant received the therapy through an intravenous infusion in January in Hong Kong. Additional patients in Hong Kong and New Zealand are now being enrolled to test multiple doses.

The Ripple Effect

This breakthrough could transform how doctors treat chronic viral infections beyond hepatitis B. The epigenetic editing technique avoids the cancer risks associated with traditional gene editing while still achieving long-lasting results from a single treatment.

For the millions of people taking daily medications to keep hepatitis B under control, this therapy represents a potential end to lifelong treatment. Virologist Fabien Zoulim at the University of Lyon notes that targeting the virus's hidden copies addresses the core problem that makes hepatitis B so persistent.

The clinical trial marks the realization of many years of work and represents a huge step toward ending what experts call a global pandemic.

#